• CEO: Anders Haegerstrand
• Chairman of the board: Jan Nilsson

Annexin Pharmaceuticals is a clinical stage biotechnology company active in the therapeutic areas ophthalmology and oncology. The company develops ANXV, a recombinant human Annexin A5 protein, as a first-in-class biologic with potentially disease-modifying mechanisms of action. The ANXV program is currently in Phase 2 in ophthalmology for retinal vein occlusion (RVO) and diabetic retinopathy (DR) and in pre-clinical stage in oncology.

The company is based in Stockholm and listed on Nasdaq First North Growth Market Sweden under the ticker ANNX. Redeye Nordic Growth AB is the company’s Certified Adviser.

• CEO: Marguerite Mensonides
• Chairman of the board: Rob Mayfield

Amplio Pharma is a rare opportunity to invest in a de-risked, patent-protected asset with the potential to redefine first-line rheumatoid arthritis treatment. NovoBioJect builds on methotrexate, the established global standard, and has already generated human biomarker data supporting superior efficacy. Rather than competing in crowded biologics markets, it aims to replace the current first-line therapy, creating access to a multi-billion-dollar market opportunity. With Phase IIa ahead, €10 million of Series A financing, and a defined acquisition pathway by major immunology players, Amplio offers investors a realistic near-term exit opportunity and the potential for outsized returns.

• CEO: Michael Malkoch
• Chairman of the board: Michael Malkoch

Every second, more than five people somewhere in the world break a bone. Most of us will break at least two in a lifetime. Fracture is not a niche indication. It is one of the few medical events almost every human being will experience.Yet the repair has barely changed in seventy years. A rigid metal plate is manufactured long before the injury exists, chosen from a catalogue of sizes and bent by hand to approximate a bone it was never made for. The compromise is sharpest where the need is greatest. In osteoporotic bone, screws lose their purchase, and a plate many times stiffer than the bone it supports shields that bone from load and concentrates stress at its ends, where the next fracture begins.

Biomedical Bonding AB is a Swedish MedTech company founded to remove that compromise. Bonevolent®, a patented light-cured composite platform spun out of KTH Royal Institute of Technology in Stockholm and grounded in more than a decade of research and peer-reviewed biomechanical evidence, allows the surgeon to build a load-bearing fixator directly on the bone and cure it on demand. The implant is shaped to the fracture rather than the fracture to the implant, and it cures to a stiffness close to bone itself.The human skeleton has 206 bones, and almost every one of them can break in a way that a fixator shaped in theatre fits better than anything made in advance. That is the scale BMB is building towards: veterinary market entry in 2027, the first human fracture fixed in 2028, followed by market launch in 2030.

• CEO: Martin Welschof
• Chairman of the board: Leonard Kruimer

BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with drug candidates in ongoing clinical programs in Phase 1/2 trials for the treatment of solid tumors and hematological cancer. Its validated, proprietary F.I.R.S.T™ technology platform identifies both targets and the antibodies that bind to them, generating many promising new immune-modulatory candidates to fuel the Company’s own clinical development pipeline and providing licensing and partnering opportunities. The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company’s fully integrated manufacturing unit. More information is available at www.bioinvent.com.

• CEO: Hilde H. Steineger
• Chairman of the board: Magnus Persson

Cantargia is a clinical-stage biotech company developing antibody therapies targeting IL1RAP, a key driver in cancer and inflammatory diseases. Our lead asset, nadunolimab, shows promising clinical activity in hard‑to‑treat cancers such as pancreatic cancer, addressing a major unmet medical need. In parallel, CAN10 creates significant value through a global partnership with Otsuka, including milestone payments and royalties. With a differentiated mechanism, advancing clinical programs, and strong partnering potential, Cantargia offers a compelling opportunity in high‑impact therapeutic areas.

• CEO: Morten Albrechtsen
• Chairman of the board: Peter Mørch Eriksen

FluoGuide lights up cancer to maximize surgical outcomes in oncology. FluoGuide’s lead product, FG001, is designed to improve surgical precision by lighting up cancer intraoperatively. The improved precision has a dual benefit – it reduces both the frequency of local recurrence post-surgery and lessens surgical sequelae. Ultimately, the improved precision enhances the likelihood of complete cure and lower healthcare costs. FluoGuide has demonstrated that FG001 is both effective and well tolerated in several phase II clinical trials. The lead indications of FG001 are aggressive brain cancer (glioblastoma) and oral head and neck cancer. FluoGuide has entered partnerships with leading MedTech companies with the aim of accelerating development and commercialization. FluoGuide is listed on Nasdaq First North Sweden under the ticker “FLUO”.

• CEO: Claus Elsborg Olesen
• Chairman of the board: Magnus Persson

Initiator Pharma A/S is a Danish clinical-stage life science company developing novel therapies targeting unmet needs in the central and peripheral nervous system through a new generation of monoamine modulators. Its lead asset, pudafensine, has demonstrated positive Phase II results in erectile dysfunction and is advancing in vulvodynia, a chronic neuropathic pain condition, with readout expected in Q4 2026. With a focused pipeline and near-term clinical milestones, Initiator Pharma is positioned to deliver differentiated treatments in underserved areas of sexual health and neuropathic pain.

• CEO: Hanna Sjöström
• Chairman of the board: Märta Lewander Xu

Neola Medical is in clinical phase aiming at U.S. launch of Neola® — a class II medical device designed to advance neonatal intensive care. Our mission is to give preterm born babies a safer and stronger start in life by empowering healthcare professionals with non-invasive, continuous lung monitoring that enables instant detection of lung collapse and provides critical insights needed to make life-saving decisions. The goal is earlier intervention, improved clinical outcomes, and a new standard of care for the most fragile patients.

• CEO: Cathrin Johansson
• Chairman of the board: Peter Marcusson

MedVasc is transforming the gold-standard treatment for varicose veins by eliminating the most painful part of thermal ablation. Our patented Solutio™ catheter delivers local anesthesia from inside the vein, improving patient comfort and clinical efficiency while integrating seamlessly into existing workflows. We are targeting a proven $1B global market, with human validation, global patent protection, and FDA 510(k) clearance planned for 2027. We are raising capital to execute a strong commercial market entry, maximize strategic partnerships, and position the company for a high-value acquisition by a leading medical device company.

• CEO: Stian Kildal
• Chairman of the board: Daniel Ehrenstråhle

OncoZenge is a clinical-stage pharma company developing BupiZenge™, a lozenge designed to help millions of people suffering from oral pain. The company’s primary indication is oral mucositis, a painful side effect of radiotherapy and chemotherapy that affects a large number of cancer patients worldwide. BupiZenge™ is currently advancing through Phase III development and has the potential to address a significant unmet medical need. Backed by a European licensing and volume supply partnership with Molteni Farmaceutici for Europe, the company is continuously engaging with prospective licensees and investors for commercialization in new markets and development opportunities, to bring this innovation and new treatment option to patients in need.

• CEO: Ulrika Warpman Berglund
• Chairman of the board: Eva Sjökvist Saers

Oxcia AB is a clinical-stage biotech company pioneering therapies that target key drivers of many diseases, using its proprietary O2-DDR platform (Oxidative stress, Oxidative DNA damage, and DNA Damage Response (DDR)). The platform has so far generated two first-in-class drug candidates: OXC-101, currently in clinical development for acute myeloid leukemia with both FDA and EMA Orphan Drug Designations, and OXC-201, a novel treatment for idiopathic pulmonary fibrosis supported by European Innovation Council funding. By addressing major unmet medical needs through a differentiated scientific approach, Oxcia aims to deliver transformative therapies to make life less short, creating significant value for patients and investors.

• CEO: Anders Kronborg
• Chairman of the board: Becki Morrison

ResoTher Pharma is a Danish biotech company developing novel resolution pharmaceuticals for better treatment of acute, hyperinflammatory disorders. Resolution therapy has potential to effectively address the pathological role of an excessive inflammation without general suppression of the immune system.Lead drug candidate, RTP-026, is in Phase2 as a potential first-in-class cardioprotectant for patients at high risk of cardiac damage after a heart attack. Phase2a results show very good safety and strong signals of cardiac tissue protection and functional restoration after PCI. A partly pre-committed private funding round shall raise capital to fund a Phase 2b PoC study (200 patients), planned to start in Q1-27 with results mid-28 – and to publicly list in Q4-26.

• CEO: Nina E Beer
• Chairman of the board: Johan Ryden

redhot Diagnostics commercializes standardized kits for LC-MS/MS, the gold-standard method in clinical chemistry. Most laboratories still run these tests on in-house protocols, so results vary from one laboratory to the next, and IVDR is steadily closing that route. redhot replaces the protocols with validated, CE-marked kits.The lead product measures PEth, a substance formed only in the presence of alcohol, giving it 100 percent biochemical specificity and a detection window of several weeks. It is used in addiction medicine, liver and transplant clinics, and clinical trials. The kit is on the market today, generating recurring revenue at gross margins above 90 percent with almost no commercial effort behind it.Kits for drug monitoring and vitamin B12 deficiency are in development, alongside rhelise™, a patented home-sampling kit that keeps a blood sample stable for more than two weeks at room temperature. A further application filed in 2026 covers improved calibrators and controls.redhot diagnostics is raising capital to expand European and US distribution and build a multi-marker LC-MS/MS platform.

• CEO: Jeppe Øvlesen
• Chairman of the board: Anders Kronborg

SynAct Pharma AB is a clinical stage biotechnology company focused on developing novel resolution therapies for inflammatory diseases. Lead program, Resomelagon, finalized Phase 2b in rheumatoid arthritis, is a potential first-in-class novel non-suppressive therapeutic opportunity that enables key immune cell modulation to reduce inflammatory activity and promote resolution. Phase 3 preparations initiated.